Abstract : The Aim of the present investigation was to formulate and evaluate Valsartan transdermal drug delivery system. A 32 full factorial design was employed to explore the effects of HPMC K4M and Polyvinyl Pyrrolidine (independent variables) on Tensile strength, % cumulative drug release at 6 hours and % cumulative drug release at 24 hours(Dependent variables). Drug-polymer compatibility studies was determined by Fourier Transform Infrared Spectroscopy. The result of compatibility study revealed that there was no interaction between drug and polymers. Results showed drug release in the range 78.73± 0.38 - 96.32±0.33 and drug content in the range of 95.49±0.444 - 98.40 ±1.21. Moisture content and moisture uptake were increased for patches containing higher amount of HPMC K4M. Patch containing HPMC K4M in higher proportion gives increase in the drug release. It indicates that as PVP K30 increase drug release was decreased. On the basis of In-Vitro drug release performance F9 was selected as the optimized formulation. Ex-vivo drug release study carried out for optimized batch and it showed 96.32±0.33 % drug release after 24 hours. F9 shows ideal higuchi release kinetic. Skin irritation study for F9 revealed that it was free of irritation. Optimized batch F9 was found to the stable at 40 ± 0.5 °C and 75 ± 5% RH during the test period of 1month.
Keyword : Valsartan, HPMC K4M, Eudragit RL 100, Polyvinyl Pyrrolidone K30, Reservoir method, Transdermal Patch, Ex-vivo study, 32Factorial Design.